Evaluate the efficacy of treatment FOLFORINOX 3 in first-line therapy for patients with locally advanced unresectable or metastatic pancreatic cancer.
Male or female age > 18 years at time of study entry
Performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG)
Patients with pancreatic adenocarcinoma
Patients with unresectable locally advanced pancreatic cancer or metastatic pancreatic cancer
Patient with neuroendocrine carcinoma or acinar cell carcinoma
Other cancer in the 5 years preceding inclusion or concomitant (except cancer in situ of the uterine cervix or cutaneous basal cell carcinoma).
Presence of brain metastasis(es)
Estimated prognosis < 3 months